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Effect of Changes in Plasma Levels of Free Fatty 
Acids on Plasma Glucagon, Insulin, and 
Growth Hormone in Man 
Brendan Ii. Hicks, Charles I. Taylor, Wish K. Vii, Sumer Pek, Ralph F. Knopf, 
John C. Floyd, Jr., and Stefan S. Fajans 
A regulatory role of acute changes in 
plasma concentration of free fatty acids on 
glucagon secretion has been suggested. 
We have studied the effect of such changes 
on plasma levels of glucagon, insulin, and 
growth hormone in man. Basal plasma 
levels of immunoreactive glucagon (IRG) 
were only slightly raised in 11 healthy 
subjects when the mean concentration of 
free fatty acids (FFA) was depressed to 
levels as low as 0.3 15 f 0.043 (SEM) mM 
by infusion of nicotinic acid. Basal levels 
were increased modestly when the mean 
FFA level was elevated to 3.027 f 0.184 
mM by infusion of a triglyceride emulsion 
(Intralipid) with heparin. The plasma IRG 
response to intravenous arginine was un- 
affected by high or low levels of plasma 
FFA. These findings contrasted with the 
effects upon plasma levels of immunoreac- 
tive insulin (IRI) and growth hormone 
(IGH). During elevation of F7A levels, the 
mean basal level of plasma IRI increased 
by lOO%, and the IRI response to arginine 
increased by 50%. Concomitantly, basal 
IGH levels and the plasma IGH response 
to arginine were suppressed markedly by 
elevation of FFA levels. The results of these 
studies do not offer support for a signifi- 
cant role of variation in plasma level of 
FFA as a regulator of acute changes in 
plasma IRG in man. An influence of chang- 
ing levels of FFA on insulin secretion was 
found, and an effect on levels of growth 
hormone was confirmed. 
M ETABOLIC SUBSTRATES such as glucose, amino acids, and free fatty acids (FFA) have important regulatory effects on a variety of hormones 
that influence the transfer of these substrates to or from energy stores. Rising 
plasma levels of glucose stimulate secretion of insulin and suppress secretion of 
glucagon and growth hormone. Opposite effects occur when plasma glucose 
levels are falling or hypoglycemia is induced. Rising levels of certain amino 
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acids evoke increased secretion of insulin, glucagon, and growth hormone. In a 
number of reports it has been suggested that in man raised FFA levels enhance 
insulin’-8 and suppress growth hormone secretion,9-‘3 but in many of these re- 
ports the concomitant changes in plasma glucose concentration have made it 
impossible to identify an independent role of FFA. Three reports of the effects 
of changes in lipid levels on plasma glucagon levels in man have recently ap- 
peared. Gerich et al. reportedI that elevated plasma FFA levels were associated 
with decreases in basal plasma glucagon and in the glucagon response to argi- 
nine, and that depressed plasma FFA was associated with an increase in basal 
plasma glucagon but no change in the response to arginine. These findings were 
interpreted as showing that alterations in plasma FFA within the physiologic 
range may have a significant effect on glucagon secretion in man, and they 
seemed to extend results obtained in animals in vivo and in vitro.‘5-‘8 On the 
other hand, the report of Andrews et a1.19 suggested only a minor role of lipids 
in the control of glucagon secretion, and that of Tiengo et aI.” included no rela- 
tionship between FFA levels and glucagon secretion in normal subjects. In the 
present studies, conducted before publication of those reports, we examined the 
effect of changing levels of FFA on glucagon, insulin, and growth hormone lev- 
els in experiments performed in random order in a group of healthy subjects. 
MATERIALS AND METHODS 
Subjects. Eleven healthy male college students who had normal oral glucose tolerance tests 
were volunteers in a regular weekly research program. They were 19-26 yr old, and their weights 
were 88%-109°/0 of “desirable weight” (Metropolitan Life Insurance Company). Consent to these 
studies was on the basis of full information, with the approval of the Human Use Committee. 
Procedures. During the 3 days preceding each experiment subjects avoided major deviations 
from their regular normal diet, then fasted and avoided medications and drugs for at least 12 hr 
before the experiment commenced at 8:00 a.m. At the start of each experiment subjects were 
quizzed concerning strict adherence to these rules (hence the cancellation of one experiment in 
the saline-arginine series). A basal observation period of 30 min was followed by a 90-min intra- 
venous infusion designed to achieve high, low, or normal FFA levels: during the last 30 min of 
this infusion a second infusion of either isotonic saline or arginine hydrochloride was added. 
Plasma concentrations of substrates and hormones were measured during these periods, and 
during a further 90 min. 
Protocols 
Five protocols were used: 
1. Saline-arginine. First infusion: 0.9% saline, 405 ml in 90 min; second infusion: 100 mg/ml 
L-arginine hydrochloride (Cutter Laboratories), 4.9 ml/kg body weight (maximum 360 ml, 36g) in 
30 min (10 of the I I subjects). 
2. Nicotinic acid-arginine. First infusion: nicotinic acid (Eli Lilly), 1 mg/kg body weight in 
20 ml saline in 1 min, then remainder of 200 mg in 405 ml saline in 89 min; second infusion: 
arginine, as above (all subjects). 
3. Intralipid-heparin-arginine. First infusion: Intralipid-heparin, 405 ml in 90 min; second 
infusion: arginine, as above (all subjects). The Intralipid-heparin solution consisted of 405 ml 
of Intralipid (lo”/, soy bean oil emulsion) (Cutter Laboratories), to which was added beef lung 
heparin (Eli Lilly), 40 units/kg body weight. 
4. Inrralipid-heparin-saline. First infusion: Intralipid with heparin as above; second infu- 
sion: 0.9% saline, 4.9 ml/kg body weight (maximum 360 ml) in 30 min (all subjects). 
These four protocols were used in the subjects in a randomized sequence, to minimize any bias. 
5. Intralipid-low heparin-arginine. First infusion: Intralipid containing heparin, 200 units, 
405 ml in 90 min; second infusion: arginine, as above (3 of the 1 I subjects). 
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Determinations 
Blood samples were put into cold heparinized and (for triglyceride estimations) plain glass 
tubes, placed immediately in ice, centrifuged at 4°C within the hour, and rapidly deep frozen. 
Quality control studies confirmed that if these procedures were followed no significant change in 
the apparent concentrations, including those of immunoreactive glucagon, occurred between the 
time of collection and that of estimation. Measurements were made at intervals as shown in the 
figures or indicated in the text. Plasma glucose was estimated by an automated glucose oxidase 
method,” plasma FFA by the technique of Dole and Meinertz,” and serum triglycerides by a 
modified method of Van Handel and Zilversmit.23 Radioimmunoassays of glucagon, growth hor- 
mone, and insulin were of the double antibody type based on the method of Morgan and Laza- 
row.24 
Immunoreactive glucagon (IRG) in plasma was determined using barbital-saline buffer, 0. I M, 
pH 8.6, containing 2.5 g/liter bovine serum albumin, crystalline beef-pork glucagon (Eli Lilly, 
lot 258-234B-167-l) as standard, and a rabbit anti-bovine-porcine-glucagon serum, G9-I. Anti- 
serum G9-I, which reacts with the carboxyl terminal of the glucagon molecule, does not react 
with gastric inhibitory polypeptide. secretin, somatostatin. or threonine-phenylalanine-threonine- 
serine tetrapeptide, nor with gastrin, insulin, or proinsulin. The affinity of the antiserum to the 
glucagonlike compounds present in a purified extract of porcine intestinal mucosa (“MUC-IOI,” 
Novo Research Institute, Copenhagen, Denmark) is 2”‘$-5”,, of its affinity to pancreatic glucagon. 
All incubation tubes contained two proteinase inhibitors to minimize the degradation of 
glucagon: aprotinin (Trasylol, FBA) 1000 kIU/tube, and benzamidine hydrochloride hydrate 
(Aldrich Chemicals) 0.01 M. The average sensitivity in 14 assays was 3.4 pg/tube. The intra- 
assay variation was 4.1%, and the interassay variation was 14%. Binding of hormones to their 
antibodies was not affected by Intralipid, palmitic acid, nicotinic acid, or heparin at plasma 
concentrations of the order reached or presumed to have been reached during these studies. 
Statistical analyses. Comparisons were evaluated by the two-tailed Student’s 1 test for paired 
and/or unpaired data. The glucagon data were also analyzed by considering values reexpressed as 
a percentage of or deviation from the average of the first three samples (-90 to -60 min), or 
deviation from the level at 0 min. All values are presented as the mean + SEM. 
RESULTS 
Plasma FFA and Serum Triglyceride 
The infusion of isotonic saline was not associated with any significant change 
in plasma FFA level (Fig. 1). At time 0 min, when the arginine infusions com- 
menced, the mean level was 0.592 + 0.072 mM. During nicotinic acid infusion 
the 0-min level was 0.315 f 0.043 mM (compared with saline infusions, p < 
0.005), while during the Intralipid-heparin infusion it was 3.027 f 0.184 mM 
(compared with saline infusions, p < 0.001). These respectively low and high 
levels of plasma FFA persisted until and for some minutes after the infusions 
ceased at +30 min. The FFA concentrations were low between 30 and 60 min 
during the saline-arginine study too, e.g., 0.383 f 0.054 mM at 60 min. 
Serum triglyceride concentrations were measured in 30 of the 46 experiments. 
There were no significant changes from the respective starting levels of 168 f 16 
and 153 f 13 mg/dl during saline or nicotinic acid infusions. During the Intra- 
lipid-heparin (40 units/kg) infusion, when arginine was the second infusion 
mean serum triglyceride level peaked at 0 min at 526 f 107 mg/dl; when saline 
was the second infusion the level peaked 30 min later at 629 f 100 mg/dl. Dur- 
ing two Intralipid-low-heparin infusions serum triglyceride concentrations were 
slightly higher than in the high-heparin experiments; the mean FFA level did 
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tinic acid, or Intralipid-heparin 
before and during infusions of 
arginine. 
Plasma Glucose 
Figure 2 illustrates that plasma glucose concentrations changed little before 
0 min and rose during arginine infusion. During and 10 min after the arginine 
infusion plasma glucose was significantly lower when nicotinic acid was infused 
than when saline or Intralipid-heparin was infused. 
Plasma Immunoreactive Glucagon 
The basal levels of plasma IRG before infusions commenced were similar for 
all protocols and remained stable during saline infusion. During infusions of 
Intralipid-heparin and of nicotinic acid there were mild mean elevations before 
the commencement of arginine, reaching 109 f 23 and 95 f 35 pg/ml, respec- 
tively, with return to basal level by 0 min in the case of nicotinic acid infusions 
(Fig. 3). A slight upward trend continued in the absence of arginine in studies 
employing Intralipid-heparin and saline, the peak at 40 min then being recorded 
as 139 f 43 pg/ml (Fig. 4). However, these curves, at specific time points or as 
the areas of the increment over the initial basal level, did not differ from one 
another significantly. The incremental areas (pg - min/ml, mean f SEM) from 
-60 to 0 min were for saline-arginine, -52.8 f 454, nicotinic acid-arginine, 
1248 f 456 (t = 0.882), and Intralipid-heparin-arginine, 6677 f 453 pg/ml. 
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The plasma IRG response to arginine was generally similar during saline, 
nicotinic acid, and Intralipid-heparin infusions (Fig. 3). Only at 7 and 30 min 
of the Intralipid-heparin-arginine study were the plasma IRG levels statistically 
significantly higher than those during the saline-arginine experiments, but not 
when the data were expressed as increments over the 0-min levels. No statis- 
tically significant differences in the plasma IRG responses were evident when 
IRG areas during the period O-120 min were compared. The 0-120-min incre- 
mental areas (pg - min/ml, mean f SEM) during and following the arginine 
infusions were, for saline-arginine, 7740 & 1850, nicotinic acid-arginine, 
14,460 f 3,045 (t = 0.804), Intralipid-heparin-arginine, 6969 f 2064 pg/ml. 
Thus the mean plasma IRG responses to arginine were very similar at high, low, 
and normal plasma levels of FFA. 
When in three subjects the plasma triglyceride levels were raised to over 500 
mg/dl by infusion of Intralipid-low-heparin (not illustrated), the glucagon re- 
sponse to arginine was again similar to that following saline. 
Plasma Immunoreactive Insulin 
During saline and nicotinic acid infusions plasma immunoreactive insulin 
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lipid-heparin infusion the mean IRI concentration rose from a basal level of 
8 f 2 to 12 f 2 punits/ml at 0 min, significantly higher than the corresponding 
level for saline infusion, 6 + 1 punits/ml (p < 0.005). In studies in which Intra- 
lipid was given together with saline, plasma IRI continued its rise to reach a 
peak level of 15 f 2 punits/ml at 40 min (Fig. 4). 
The IRI response to arginine was lower when nicotinic acid was infused as 
compared to control, but only at 3-min (24 f 5 versus 45 + 8 p units/ml, p < 
0.05) and 5-min (35 f 4 versus 49 f 5 qnits/ml, p < 0.05) time points (Fig. 5). 
The overall response, however, was not significantly reduced as judged by the 
area of increased IRI concentration under the curve, which was only about 15% 
less than the control value. During Intralipid-heparin infusion the IRI response 
to arginine was much augmented, peak concentration at 30 min reaching a 
mean of 107 f 17 as compared to the control of 66 f 11 punits/ml, p < 0.02. 
The mean rise in IRI concentration between 0 and 30 min, and during the argi- 
nine infusion, was 95 f 17 with Intralipid as opposed to 61 f 12 punits/ml 
without (p < 0.05), indicating that this augmentation was more than a simple 
elevation of starting level. Similar augmentation of the IRI response was also 
seen in three experiments of the low-heparin type (not illustrated), in which 
mean FFA levels rose only to 1.195 mA4. 
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Changes in Plasma Immunoreactive Growth Hormone 
During the infusion of nicotinic acid, plasma levels of immunoreactive 
growth hormone (IGH) rose from a mean value of 0.7 f 0.2 ng/ml at -60 min 
to 2.5 f 1.4 at - 15 min and 1.9 f 0.8 ng/ml at 0 min (Fig. 6). In contrast, 
Intralipid-heparin was associated with a downward drift of IGH to 0.7 f 0.2 
ng/ml at 0 min, and, if an infusion of saline was then added (Fig. 4), by a fur- 
ther downward drift to a nadir of 0.5 f 0.1 ng/ml at 30 min. During this Intra- 
lipid-heparin-saline experiment mean plasma IGH levels between 0 and 105 
min were significantly lower than the mean basal value (p < 0.05), and the 
mean area under the growth hormone curves between -60 and 0 min for all 
Intralipid-heparin experiments was significantly less, at 15.1 f 4.1 ng - min/ml, 
than the same area when only saline was infused, 28.5 f 6.9 ng - min/ml (p < 
0.03). 
During the period from -60 to 60 min within which Intralipid-heparin and 
saline were infused (Fig. 4), the growth hormone area was less than one-half the 
area under the curve between -60 and 0 min in studies in which saline alone 
was infused (-46.6 & 17 versus 57.1 f 7.1 ng - min/ml, 
PLASMA LEVELS OF FREE FATTY ACIDS 
Table 1. Peak levels of Plasma Growth Hormone in Response to Arginine 
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NS <0.02 <O.OOl 
NS <O.Ol <0.005 
-a.57 12.67 
f 2.57 f 2.91 
Individual and mean peak levels of plasma IGH (ng/ml) in response to arginine infusions during sa- 
line, nicatinic acid, or Introlipid-heparin infusions (normal, law, and high FFA conditions, respectively) (SA, 
NAA, and IHA, respectively). NS, not significant. 
levels were 10.5 + 2.7 and 14.8 f 4.1 ng/ml, respectively (Table 1), and the 
mean area under the curve between 0 and 120 min (0-min value used as base- 
line) was greater during nicotinic acid infusion (597 f 218 ng . min/ml) than 
the control (saline-arginine) (388 + 144 ng . min/ml), but these differences were 
not statisticaily significant. 
When Intralipid-heparin was infused, the IGH response to arginine was vir- 
tually abolished, the suppression (as compared to levels during saline-arginine) 
being seen in nine of ten subjects (Table l), and it was statistically significant 
at 30-90 min (Fig. 6). The area under the curve was also significantly less, 
55 =t 22 versus 388 i 144 ng. min/ml (p -C 0.05). In the three studies employ- 
ing low doses of heparin (not illustrated) no effect of lipid upon IGH levels 
could be detected. 
DISCUSSION 
The findings in relation to growth hormone (Fig. 6) confirm and extend those 
of Blackard et al.,‘O who reported that an almost complete suppression of IGH 
response to arginine occurred in the presence of elevated FFA levels and that 
neither elevation of triglycerides nor the injection of heparin had this effect. 
Others have recorded suppression by FFA of the sleep-induced IGH peak” and 
the IGH response to beefsteak, ” but not of exercise-induced growth hormone 
secretion.2s The Intralipid-heparin-saline experiments also demonstrated that 
basal levels of IGH are suppressed when FFA levels are elevated. This effect on 
basal growth hormone secretion has been previously reported only in baboons.26 
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During infusion of nicotinic acid IGH levels gradually rose, and under these 
conditions arginine provoked an IGH response 50% greater than during control 
experiments. Although the finding was not statistically significant, it should be 
viewed in the light of the report of Quabbe et a1.i3 They demonstrated a basal 
IGH increase during and after nicotinic acid while FFA levels were low. They 
also showed that this increase was blocked by lipid-heparin infusion but not by 
glucose, indicating the potency of the FFA effect and providing reassurance 
that the increases in IGH are unlikely to be mere responses to stress induced by 
nicotinic acid. The two subjects of ours who suffered transient discomfort with 
nicotinic acid showed the lowest IGH levels overall. 
During Intralipid-heparin infusions basal levels of plasma IRI increased to a 
statistically significant degree (Figs. 4 and 5). Many previous studies in man of 
basal insulin have failed to show any change following orally’,‘** or intra- 
venously ‘*‘J’,~* administered lipid or heparin.14 Only Pi-Sunyer et al.5 found 
modest rises in insulin levels, in subjects who had ingested meals of medium- 
chain triglycerides or corn oil, but FFA levels were not measured. In our experi- 
ments, during the basal period small (2-3 mg/dl) and transient increases in 
plasma glucose (Figs. 2 and 4) and small rises in plasma IRG (Figs. 3 and 4) 
occurred, but the size and timing of these changes were such that they were 
probably not an important factor in the insulin response. 
A marked augmentation of the plasma IRI response to infused arginine was 
seen (Fig. 5) during Intralipid-heparin studies. During Intralipid-low-heparin 
experiments, the smaller increases in FFA (mean maximal level of 1.195 mM) 
were also accompanied by augmentation of arginine-induced insulin release. In 
another study, when mean plasma FFA was raised to about 0.70 mM by 
heparin injection alone, no augmentation of arginine-induced insulin release 
was observed.14 In the presence of high FFA concentrations the insulin response 
to intravenous glucose has been reported by some to be unaffected,27 by some to 
be increased in the presence of abnormally high glucose values,2*8 and by others 
to be potentiated even in the presence of lower glucose levels.4 
The mechanisms by which basal and arginine-induced insulin release are 
enhanced during infusions of Intralipid and heparin are not known, but they 
are unlikely to include effects of ketones,29-32 triglycerides,2*28 or glycerol.4q33 In 
the dog34 direct infusion of long-chain FFA into the pancreatic artery, achieving 
local concentrations between 0.6 and 0.8 mM, resulted in increased insulin se- 
cretion; thus an effect of FFA on the &cell is likely to exist. 
We found little evidence that depression of FFA levels could be a factor in 
the control of insulin secretion. Only at the 3- and 5-min time points of the 
arginine infusions was plasma IRI significantly lower in the presence of nico- 
tinic acid, and at this time the plasma glucose was about 5 mg/dl lower. Balasse 
and Ooms* did show a depressant effect of nicotinic acid injections on plasma 
insulin responses to glucose, glucagon, and tolbutamide (arginine was not em- 
ployed). They interpreted their data as showing also that lowering plasma FFA 
resulted in a significant fall in basal plasma insulin, but the “suppressed” levels 
in the low-FFA study were close to basal levels in other experiments in the 
study. Apart from decreases in plasma FFA similar to those reported here, the 
experimental conditions were different: 100 mg of nicotinic acid was injected 
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every 15 min over a period of 3 hr, a total of 1200 mg, and those studied were 
obese, being 122%-183x of “ideal weight.” 
We have not been able to demonstrate any definite influence of elevated or 
depressed plasma FFA levels on plasma IRG. We did note modest increases in 
plasma IRG when plasma FFA was elevated to supraphysiologic levels by 
Intralipid-heparin infusion. In this connection the effects of the small amounts 
of glycerol, 2.5%, and egg yolk phospholipid, I .2%, contained in Intralipid are 
not known, but an effect of the FFA cannot be excluded. 
When Gerich et al.14 raised FFA levels to 0.712 mM by injecting 5000 units 
heparin intravenously every 15 min, they noted decreases in basal levels of 
plasma glucagon; a mean basal level of 122 pg/ml fell to 59 pg/ml. Andrews et 
a1.19 reported suppression of the mean basal glucagon level of 128 pg/ml to 
82 pg/ml when FFA levels were elevated by ingestion of Lipomul (Upjohn) 
(containing 60 g corn oil) and injection of 5000 units heparin, or by infusing 
Intralipid-heparin. It may be relevant that initial “basal” levels were somewhat 
high in these studies. Although both groups reported suppression of basal 
plasma glucagon when plasma FFA was elevated, only Gerich et a1.14 found 
that the glucagon response to arginine was reduced. As reported herein, Black- 
ard et a1.19 found no suppression of the plasma glucagon response to arginine. 
In contrast to our findings, when plasma levels of FFA were lowered by two 
200-mg injectionsI or a 30-min 400-mg infusion” of nicotinic acid, basal levels 
of glucagon increased. Blackard et a1.,19 who reported an increase from 73 to 
137 pg/ml, concluded that the increases in basal plasma glucagon noted during 
nicotinic acid infusion were induced by stress or some related factor; the same 
rise in glucagon was seen when they infused nicotinic acid and Intralipid- 
heparin simultaneously and thereby prevented the fall in FFA concentration 
but not the symptoms related to nicotinic acid. We (Fig. 6) and othersI have 
noted early during nicotinic acid administration an occasional increase in 
plasma IGH only. Perhaps we could demonstrate only a modest transient in- 
crease in plasma IRG during administration of nicotinic acid because we ad- 
ministered a total of only 200 mg nicotinic acid over a period of 120 min, 
whereas others administered 400 mg during 1 514 and 3019 min. In neither of the 
other acute studies’4,‘9 nor in this study was the plasma IRG response to argi- 
nine influenced by nicotinic acid or low FFA levels. 
In a controlled study of patients with hypertriglyceridemia before and after 
2-4 mo treatment with clofibrate, Tiengo et al.*’ found no correlation between 
FFA and glucagon fasting levels or response to arginine, but they did find an 
increased glucagon response in the patients as compared to controls that was 
further increased by treatment with clofibrate. 
It must be stated that in in vivo’5*‘6 and in vitro’7,‘s animal experiments the 
weight of evidence, although not extensive, would support the existence of an 
inhibitory influence of FFA at the a-cell. However, it is entirely possible that 
the balance of substrates and hormonal influences operating in the various ani- 
mal species are quite different from those in man. On the basis of differing pro- 
tocols and findings, the evidence in man that plasma levels of FFA may exert 
physiologic influence upon glucagon secretion is equivocal. Thus in just one of 
six sets of experiments in this study and in two other acute studies was there an 
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effect upon arginine-stimulated release of glucagon. The fact that alteration of 
plasma FFA within the physiologic range had a significant effect on basal levels 
of plasma glucagon in their experiments led Gerich et al.14 to conclude that 
changes in plasma FFA may exert a physiologic influence over human pan- 
creatic a-cell function, but the results of our studies do not suggest that varia- 
tions in plasma levels of FFA play a significant role in the regulation of gluca- 
gon secretion in man. Andrews et al. I9 showed that supraphysiologic plasma 
levels of FFA, although suppressing basal glucagon, did not suppress arginine- 
or hypoglycemia-induced glucagon secretion in man. They and Tiengo et al.” 
also concluded that if FFA have a physiologic role in regulation of glucagon 
secretion, then it must be a minor one. 
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